Clinical Trial Update: Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study [Phase 2]

View source ↗

Summary

This update describes an open-label, randomized Phase 2 trial evaluating toripalimab with or without sequential intravesical gemcitabine-mitomycin C for patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer
• Transitional Cell Carcinoma of the Bladder
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Mitomycin-C (mitomycin C)
• Toripalimab (Toripalimab)

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Status: NOT_YET_RECRUITING